ARCA biopharma has reported topline results from Phase IIb ASPEN-COVID-19 clinical trial of its therapy rNAPc2 (AB201) to potentially treat hospitalised Covid-19 patients. 

A highly selective tissue factor inhibitor, rNAPc2 has anti-inflammatory, anticoagulant and potential antiviral effects.

The multicentre, randomised trial assessed two doses of rNAPc2 versus standard of care of heparin in 160 Covid-19 patients in hospital with increased D-dimer levels. 

A biomarker, D-dimer is utilised to evaluate coagulation activation, which is usually raised in hospitalised Covid-19 patients and is linked to adverse clinical outcomes. 

Heparin is an anticoagulant administered to hospitalised Covid-19 patients in the US.

The variation in D-dimer level from baseline to day eight versus heparin is the primary endpoint of the trial. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company concluded subject enrolment in the trial of rNAPc2 for Covid-19, in December last year.

Findings showed that for the complete cohort of Covid-19 patients in the hospital setting, the pooled lower and higher rNAPc2 dose arms showed a decline compared to baseline in D-dimer levels of 16.8% versus 11.2% in the heparin arm.

Even though both doses showed a treatment benefit in trial subjects, none of the doses attained statistical significance for the primary efficacy endpoint versus heparin.

Variation in D-dimer levels from baseline at day eight in the per protocol analysis showed a decline of 28.7% in the rNAPc2 dose pooled group versus a rise of 1.1% in subjects who received heparin.

Assessment on an adapted WHO COVID-19 Severity Scale showed that the D-dimer levels reduced from baseline in mild patients but rose in severe patients in the heparin group while no changes were reported in the rNAPc2 arms.

A numerical imbalance favouring rNAPc2 treatment, which was not significant, was reported on the secondary endpoints assessing thrombotic events and time-to-recovery.

In addition, rNAPc2 was demonstrated to be well-tolerated at both the tested doses without any serious treatment-associated adverse events noted.

ARCA biopharma president and CEO Dr Michael Bristow said: “At this time, ARCA is not planning further clinical development of rNAPc2 in Covid-19 in a direct superiority comparison to heparin design. 

“However, we believe the safety margin and apparent efficacy at the lower dose would not preclude a study design evaluating a prophylactic heparin-rNAPc2 combination.”